Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.
Patients 8 years of age and older who have received no previous treatment may be started on primidone tablets according to the following regimen using either 50 mg or scored 250 mg primidone tablets: Days 1 to 3: 100 to 125 mg at bedtime Days 4 to 6: 100 to 125 mg b.i.d. Days 7 to 9: 100 to 125 mg t.i.d. Day 10 to maintenance: 250 mg t.i.d. For most adults and children 8 years of age and over, the usual maintenanc...
www.aedpregnancyregistry.orgAnticonvulsant
Chemical name: 5-ethyldihydro- 5-phenyl-4,6 (1H, 5H) pyrimidinedione.
Structural formula:
C12H14N2O2
Primidone is a white crystalline powder, M.P. 279-284°C. It is very slightly soluble in methanol and methylene dichloride, slightly soluble in alcohol and insoluble in water. It possesses no acidic properties, in contrast to its barbiturate analog.
Primidone tablets 50 mg and 250 mg contain the following inactive ingredients: lactose monohydrate, magnesium stearate, methyl cellulose, purified water, sodium lauryl sulphate, sodium starch glycolate and talc.
Primidone tablets 250 mg also contain yellow iron oxide.
Primidone raises electro- or chemoshock seizure thresholds or alters seizure patterns in experimental animals. The mechanism(s) of primidone’s antiepileptic action is not known.
Primidone per se has anticonvulsant activity as do its two metabolites, phenobarbital and phenylethylmalonamide (PEMA). In addition to its anticonvulsant activity, PEMA potentiates the anticonvulsant activity of phenobarbital in experimental animals.
Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy.
Primidone tablet is contraindicated in:
1) patients with porphyria and
2) patients who are hypersensitive to phenobarbital (see CLINICALPHARMACOLOGY).
The abrupt withdrawal of antiepileptic medication may precipitate status epilepticus. The therapeutic efficacy of a dosage regimen takes several weeks before it can be assessed.
Antiepileptic drugs (AEDs), including primidone, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.
Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide.
The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.
The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.
Table 1 shows absolute and relative risk by indication for all evaluated AEDs.
Table 1 Risk by indication for antiepileptic drugs in the pooled analysis
| Indication | Placebo Patientswith Events Per1000 Patients | Drug Patientswith Events Per1000 Patients | Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients | Risk Difference: Additional Drug Patients with Events Per 1000 Patients |
| Epilepsy | 1.0 | 3.4 | 3.5 | 2.4 |
| Psychiatric | 5.7 | 8.5 | 1.5 | 2.9 |
| Other | 1.0 | 1.8 | 1.9 | 0.9 |
| Total | 2.4 | 4.3 | 1.8 | 1.9 |
The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications.
Anyone considering prescribing primidone or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
To provide information regarding the effects of in utero exposure to primidone, physicians are advised to recommend that pregnant patients taking primidone enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. This can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. Information on the registry can also be found at the website www.aedpregnancyregistry.org.
The effects of primidone in human pregnancy and nursing infants are unknown.
Recent reports suggest an association between the use of anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to these women. Data are more extensive with respect to diphenylhydantoin and phenobarbital, but these are also the most commonly prescribed anticonvulsants; less systematic or anecdotal reports suggest a possible similar association with the use of all known anticonvulsant drugs.
The reports suggesting an elevated incidence of birth defects in children of drugtreated epileptic women cannot be regarded as adequate to prove a definite cause and effect relationship.
There are intrinsic methodologic problems in obtaining adequate data on drug teratogenicity in humans; the possibility also exists that other factors leading to birth defects, e.g., genetic factors or the epileptic condition itself, may be more important than drug therapy. The great majority of mothers on anticonvulsant medication deliver normal infants. It is important to note that anticonvulsant drugs should not be discontinued in patients in whom the drug is administered to prevent major seizures because of the strong possibility of precipitating status epilepticus with attendant hypoxia and threat to life. In individual cases where the severity and frequency of the seizure disorders are such that the removal of medication does not pose a serious threat to the patient, discontinuation of the drug may be considered prior to and during pregnancy, although it cannot be said with any confidence that even minor seizures do not pose some hazard to the developing embryo or fetus.
The prescribing physician will wish to weigh these considerations in treating or counseling epileptic women of childbearing potential. Neonatal hemorrhage, with a coagulation defect resembling vitamin K deficiency, has been described in newborns whose mothers were taking primidone and other anticonvulsants. Pregnant women under anticonvulsant therapy should receive prophylactic vitamin K1 therapy for one month prior to, and during, delivery.
The total daily dosage should not exceed 2 g. Since primidone therapy generally extends over prolonged periods, a complete blood count and a sequential multiple analysis-12 (SMA-12) test should be made every six months.
There is evidence in mothers treated with primidone, the drug appears in the milk in substantial quantities. Since tests for the presence of primidone in biological fluids are too complex to be carried out in the average clinical laboratory, it is suggested that the presence of undue somnolence and drowsiness in nursing newborns of primidone-treated mothers be taken as an indication that nursing should be discontinued.
Suicidal Thinking and Behavior- Patients, their caregivers, and families should be counseled that AEDs, including primidone, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts, behavior, or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.
Patients should be encouraged to enroll in the NAAED Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll free number 1-888-233-2334 (see Usage in Pregnancy section).
Please refer to the Primidone Tablets USP Medication Guide provided with the product for more information.
The most frequently occurring early side effects are ataxia and vertigo. These tend to disappear with continued therapy, or with reduction of initial dosage. Occasionally, the following have been reported: nausea, anorexia, vomiting, fatigue, hyperirritability, emotional disturbances, sexual impotency, diplopia, nystagmus, drowsiness and morbilliform skin eruptions. Granulocytopenia, agranulocytosis, and redcell hypoplasia and aplasia, have been reported rarely. These and, occasionally, other persistent or severe side effects may necessitate withdrawal of the drug. Megaloblastic anemia may occur as a rare idiosyncrasy to primidone and to other anticonvulsants. The anemia responds to folic acid without necessity of discontinuing medication.
Patients 8 years of age and older who have received no previous treatment may be started on primidone tablets according to the following regimen using either 50 mg or scored 250 mg primidone tablets:
Days 1 to 3: 100 to 125 mg at bedtime
Days 4 to 6: 100 to 125 mg b.i.d.
Days 7 to 9: 100 to 125 mg t.i.d.
Day 10 to maintenance: 250 mg t.i.d.
For most adults and children 8 years of age and over, the usual maintenance dosage is three to four 250 mg primidone tablets in divided doses (250 mg t.i.d. or q.i.d.). If required, an increase to five or six 250 mg tablets daily may be made but daily doses should not exceed 500 mg q.i.d.
| INITIAL:ADULTS AND CHILDREN OVER 8 | ||||||
|---|---|---|---|---|---|---|
| KEY:• = 50 mg tablet; ● = 250 mg tablet | ||||||
| DAY | 1 | 2 | 3 | 4 | 5 | 6 |
| AM | •• | •• | •• | |||
| NOON | ||||||
| PM | •• | •• | •• | •• | •• | •• |
| DAY | 7 | 8 | 9 | 10 | 11 | 12 |
| AM | •• | •• | •• | ● | Adjust to Maintenance | |
| NOON | •• | •• | •• | ● | ||
| PM | •• | •• | •• | ● | ||
Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations of primidone tablets may be necessary for optimal dosage adjustment. The clinically effective serum level for primidone tablets is between 5 to 12 μg/mL.
Primidone tablets should be started at 100 to 125 mg at bedtime and gradually increased to maintenance level as the other drug is gradually decreased. This regimen should be continued until satisfactory dosage level is achieved for the combination, or the other medication is completely withdrawn. When therapy with primidone tablets alone is the objective, the transition from concomitant therapy should not be completed in less than two weeks.
For children under 8 years of age, the following regimen may be used:
Days 1 to 3: 50 mg at bedtime
Days 4 to 6: 50 mg b.i.d.
Days 7 to 9: 100 mg b.i.d.
Day 10 to maintenance: 125 mg t.i.d. to 250 mg t.i.d.
For children under 8 years of age, the usual maintenance dosage is 125 to 250 mg three times daily or, 10 to 25 mg/kg/day in divided doses.
Primidone tablets USP, 50 mg are white to off white, round, flat, beveled edged uncoated tablets debossed “RDY” and “477” on the periphery on one side and break line on other side. They are supplied in bottles of 30’s, 60’s, 100’s, 500’s and unit dose package of 100 (10 x 10).
Bottles of 30 NDC 55111-477-30
Bottles of 60 NDC 55111-477-60
Bottles of 100 NDC 55111-477-01
Bottles of 500 NDC 55111-477-05
Unit Dosage Package of 100 (10 x 10) NDC 55111-477-78
Primidone tablets USP, 250 mg are cream to yellow, round, flat, beveled edged uncoated tablets debossed “RDY” and “476” on the periphery on one side and break line on other side. They are supplied in bottles of 30’s, 60’s, 100’s, 500’s and unit dose package of 100 (10 x 10).
Bottles of 30 NDC 55111-476-30
Bottles of 60 NDC 55111-476-60
Bottles of 100 NDC 55111-476-01
Bottles of 500 NDC 55111-476-05
Unit Dosage Package of 100 (10 x 10) NDC 55111-476-78
Store at 20°–25° C (68°–77° F) [See USP Controlled Room Temperature].
Dispense in a well-closed container with a child-resistant closure.
PRIMIDONE TABLETS USP
Read this Medication Guide before you start taking primidone and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment.
What is the most important information I should know about primidone?
Do not stop taking primidone without first talking to your healthcare provider.
Stopping primidone suddenly can cause serious problems.
Primidone can cause serious side effects, including:
1. Like other antiepileptic drugs, primidone may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.
Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:
How can I watch for early symptoms of suicidal thoughts and actions?
Call your healthcare provider between visits as needed, especially if you are worried about symptoms.
Do not stop primidone without first talking to a healthcare provider.
Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.
What is primidone?
Primidone is a prescription medicine used alone or with other medicines to treat people with:
Who should not take primidone?
Do not take primidone if you: have a genetic disorder called porphyria are allergic to phenobarbital
What should I tell my healthcare provider before taking primidone?
Before you take primidone, tell your healthcare provider if you:
Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking primidone with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider.
Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist each time you get a new medicine.
How should I take primidone?
Take primidone exactly as prescribed.
What should I avoid while taking primidone?
What are the possible side effects of primidone? See " What is the most important information I should know about primidone?”
Primidone may cause other serious side effects including:
The most common side effects of primidone include:
These are not all the possible side effects of primidone. For more information, ask your healthcare provider or pharmacist.
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store primidone?
Store Primidone tablets at 20° - 25° C (68° - 77° F) [See USP Controlled Room Temperature]. in a tight, light-resistant container.
Keep primidone and all medicines out of the reach of children.
General Information about primidone
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use primidone for a condition for which it was not prescribed. Do not give primidone to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about primidone. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about primidone that is written for health professionals.
For more information, call 1-888-375-3784
What are the ingredients in primidone?
Active Ingredient: Primidone
Inactive ingredients: Lactose monohydrate, magnesium stearate, methyl cellulose, purified water, sodium lauryl sulphate, sodium starch glycolate and talc. Primidone tablets 250 mg also contain yellow iron oxide.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
To reorder additional Medication Guides, contact Dr. Reddy’s Customer Service at 1-866-733-3952.
Rx only
Manufactured by:
Dr. Reddy’s Laboratories Limited
Bachepalli – 502 325 INDIA
Revised: 1210
Primidone Tablets USP, 50 mg - Container
Primidone Tablets USP, 50 mg - Carton
Primidone Tablets USP, 250 mg - Container
Primidone Tablets USP, 250 mg - Carton
| Class | Version | Type | Effective |
|---|---|---|---|
| PRIMIDONE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 3a6e0ba9-1dda-c47a-a8e3-5844e445a4f8 | Product name | 3 | 20250114 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 55111-476-01 | Primidone | 100 in 1 BOTTLE | TABLET | 100 | 3 | |
| 55111-476-05 | Primidone | 500 in 1 BOTTLE | TABLET | 500 | 3 | |
| 55111-476-30 | Primidone | 30 in 1 BOTTLE | TABLET | 30 | 3 | |
| 55111-476-60 | Primidone | 60 in 1 BOTTLE | TABLET | 60 | 3 | |
| 55111-476-78 | Primidone | 10 in 1 CARTON | TABLET | 10 | 3 | |
| 55111-476-79 | Primidone | 10 in 1 BLISTER PACK | TABLET | 10 | 3 | |
| 55111-477-01 | Primidone | 100 in 1 BOTTLE | TABLET | 100 | 3 | |
| 55111-477-05 | Primidone | 500 in 1 BOTTLE | TABLET | 500 | 3 | |
| 55111-477-30 | Primidone | 30 in 1 BOTTLE | TABLET | 30 | 3 | |
| 55111-477-60 | Primidone | 60 in 1 BOTTLE | TABLET | 60 | 3 | |
| 55111-477-78 | Primidone | 10 in 1 CARTON | TABLET | 10 | 3 | |
| 55111-477-79 | Primidone | 10 in 1 BLISTER PACK | TABLET | 10 | 3 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 55111-476 | PRIMIDONE TABLET [DR. REDDY'S LABORATORIES LIMITED] | 3 | Current NDC, Legacy NDC, 6 package rows | 20171206_a4f917f4-2aa2-c3ed-071e-232fa0f125e8.zip |
| 55111-477 | PRIMIDONE TABLET [DR. REDDY'S LABORATORIES LIMITED] | 3 | Current NDC, Legacy NDC, 6 package rows | 20171206_a4f917f4-2aa2-c3ed-071e-232fa0f125e8.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 55111-477-01 | EA - Each | 55111-477 | 3fd1ea19-94c9-401f-98b6-012c9eee6a12 | 1 | 2012-07-24 |
| 55111-476-01 | EA - Each | 55111-476 | d823aa95-5571-4058-9ae1-db4d4295856a | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| primidone | ACTIVE INGREDIENT | 13AFD7670Q | 2 | |
| primidone | ACTIVE MOIETY | 13AFD7670Q | 2 | |
| ferric oxide yellow | INACTIVE INGREDIENT | EX438O2MRT | 2 | |
| lactose monohydrate | INACTIVE INGREDIENT | EWQ57Q8I5X | 2 | |
| magnesium stearate | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| sodium lauryl sulfate | INACTIVE INGREDIENT | 368GB5141J | 2 | |
| sodium starch glycolate type A potato | INACTIVE INGREDIENT | 5856J3G2A2 | 2 | |
| talc | INACTIVE INGREDIENT | 7SEV7J4R1U | 2 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 55111-477 | 55111-477-30, 55111-477-60, 55111-477-01, 55111-477-05, 55111-477-79, 55111-477-78 |
| 55111-476 | 55111-476-30, 55111-476-60, 55111-476-01, 55111-476-05, 55111-476-79, 55111-476-78 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| sodium lauryl sulfate | SODIUM LAURYL SULFATE | 368GB5141J | TABLET / ORAL | 233 mg | ||
| magnesium stearate | MAGNESIUM STEARATE | 70097M6I30 | TABLET / ORAL | 980 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg | ||
| talc | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| ferric oxide yellow | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET / ORAL | 24 mg | ||
| lactose monohydrate | LACTOSE MONOHYDRATE | EWQ57Q8I5X | TABLET / ORAL | 4384 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A040862-001 | PRIMIDONE | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | ||
| A040862-002 | PRIMIDONE | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 301d65b070ca… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 1e350fbaab3a… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 8072bd15b7f6… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A040862-001 | PRIMIDONE | 50MG | TABLET / ORAL | 2008-10-03 | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A040862-002 | PRIMIDONE | 250MG | TABLET / ORAL | 2008-10-03 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Primidone | PRIMIDONE | Dr. Reddy's Laboratories Limited | a4f917f4-2aa2-c3ed-071e-232fa0f125e8 | 2010-12-02 | Warnings, Adverse reactions | 55111-476-30 55111-477-30 55111-476-79 55111-476-05 55111-477-78 55111-477-60 55111-477-05 55111-476-60 55111-476-78 55111-477-79 55111-477-01 55111-476-01 55111-477 55111-476 55111047701 55111047779 55111047630 55111047730 55111047660 55111047705 55111047605 55111047679 55111047778 55111047760 55111047601 55111047678 6f5c36d3-3f99-803c-5be6-66b2e1058946 a4f917f4-2aa2-c3ed-071e-232fa0f125e8 |
Adverse event summaries are temporarily unavailable. Other product information remains available.